期刊文献+

氟维司群对乳腺癌细胞迁移及局部黏着斑激酶的影响 被引量:3

Effects of fulvestrant on the migration and focal adhesion kinase in breast cancer cells
下载PDF
导出
摘要 背景与目的:雌激素(estrogen,E2)受体(estrogen receptor,ER)拮抗剂氟维司群(fulvestrant或ICI182780,ICI)是治疗绝经后妇女乳腺癌的新型药物,而局部粘着斑激酶(focal adhesion kinase,FAK)与乳腺癌转移密切相关。本研究通过观察E2和ICI单独或联合作用对ER阳性乳腺癌细胞迁移及FAK表达的影响,探讨ICI对肿瘤细胞迁移的作用及其与FAK的关系。方法:采用E邸日性MCF-7乳腺癌细胞为研究模型,以E2(包括酒精,EtOH)和ICI单独或联合刺激细胞,采用蛋白质印迹法(Westernblot)检测蛋白表达及相对分子质量变化,伤口愈合实验检测细胞迁移变化。结果:E2(10nmol/L)和EtOH(0.3%)组均可明显刺激MCF-7细胞迁移(与DMSO组比较,分别增加51.5%和53.6%,P〈0.01),但E2+EtOH组对细胞迁移并无协同作用(与DMSO组比较,增加45.0%)。以ICI(10μmol/L)预处理细胞后再给予E2处理,与对照组比较,细胞迁移增加了(38.9±4.9)%(P〈0.01),与E2组比较减少了(8.32±3.21)%(P〈0.05);ICI单独作用可明显促进细胞迁移(与DMSO组比较,增加19.1%,P〈0.01)。对照组细胞FAK主要为125×10^3和110×10^3两种形式,E2刺激可诱导FAK(125×10^3)呈现时间依赖性蛋白剪切,生成相对分子质量为35×10^3-70×10^3的小分子片段,而ICI预处理可有效阻断E2诱导的p125FAK蛋白剪切反应。结论:ICI单独作用可明显刺激MCF-7乳腺癌细胞迁移,但ICI对E2诱导的MCF-7细胞迁移具有抑制作用,该抑制效应可能与ICI阻断FAK蛋白剪切有关。 Background and purpose: Fulvestrant (ICI182780, ICI) is a novel anti-estrogan drug for treatment of metastatic breast cancer, and focal adhesion kinase (FAK) is strongly involved in metastasis of breast cancer. This study was performed to investigate the impact of ICI on the estrogen (E2)-induced cell migration and its association with expression of FAK in estrogen receptor (ER)-positive breast cancer cells. Methods: ER- positive MCF-7 breast cancer cells were employed as a model system. E2, ethanol (EtOH) or ICI was used alone or in combination to treat model cells. Western blot was applied to analyze protein expression and wound healing assay to assess cell migration. Results: Both E2 and EtOH stimulated significant migration of MCF-7 cells, but no cooperative effect was observed. Importantly, ICI had significant inhibitory effect on E2-induced migration, while ICI, when used alone, also enhanced cell migration. When cells were not insulted, FAK was primarily expressed in the forms of 125 × 10^3 and 110× 10^3, and E2 treatment triggered cleavage of FAK (p 125) into low molecular isoforms. E2 treatment produced time-dependent proteolysis of FAK and this effect was blocked by pretreatment with ICI. Conclusion: ICI stimulates cell migration in MCF-7 cells when used alone, while it inhibits E2-enhanced migration possibly by blocking proteolysis of FAK.
出处 《中国癌症杂志》 CAS CSCD 北大核心 2013年第3期179-183,共5页 China Oncology
基金 国家自然科学基金(No:30860093) 贵州省优秀人才省长专项基金[No:黔省专合字(2008)56号]
关键词 氟维司群 细胞迁移 局部黏着斑激酶 雌激素 乳腺癌 Fulvestrant Cell migration Focal adhesion kinase Estrogen Breast cancer
  • 相关文献

参考文献13

  • 1MCKEAGE K, CURRAN M P, PLOSKER G L. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy [ J ] . Drugs, 2004, 64(6): 633-648.
  • 2王佳玉,袁芃,马飞,樊英,张频,李青,徐兵河.氟维司群治疗绝经后转移性乳腺癌患者的疗效及安全性[J].中国癌症杂志,2011,21(6):461-464. 被引量:9
  • 3KONG X, LI G, YUAN Y, et al. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression [ J ] . PLoS One, 2012, 7(8): e41523.
  • 4OHSHIRO K, SCHWARTZ A M, LEVINE P H, et al. Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling [ J ] . PLoS One, 2012, 7(1): e30725.
  • 5MATHEW A C, RAJAH T T, HURT G M, et al. Influence of antiestrogens on the migration of breast cancer ceils using an in vitro wound model [ J ] . Clin Exp Metastasis, 1997, 15(4): 393-399.
  • 6HOU J, WANG X, LI Y, et al. 17beta-estradiol induces both up-regulation and processing of cyclin E in a calpain- dependent manner in MCF-7 breast cancer cells [ J ] . FEBS Lett, 2012, 58(6): 892-896.
  • 7SANCHEZ A M, FLAMIN1 M I, BALDACCI C. et al. Estrogen receptor-{alpha} promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP [ J ] . Mol Endocrinol, 2010, 24(11): 2114-2125.
  • 8VAETH P A, SATARIANO W A. Alcohol consumption and breast cancer stage at diagnosis [ J ] . Alcohol Clin Exp Res, 1998, 22(4): 928-934.
  • 9WEISS H A, BRINTON L A, BROGAN D, et al. Epidemiology of in situ and invasive breast cancer in women aged under 45 [ J ] . BrJ Cancer, 1996, 73(10): 1298-1305.
  • 10CHAN K T, BENNIN D A, HUTTENLOCHER A. Regulation of adhesion dynamics by calpain-mediated proteolysis of focal adhesion kinase (FAK) [ J ] . J Biol Chem. 2010, 285(15): 11418-11426.

二级参考文献17

  • 1I. Vergote,J.F.R. Robertson,U. Kleeberg,G. Burton,C.K. Osborne,L. Mauriac.Postmenopausal Women who Progress on Fulvestrant (’Faslodex’) Remain Sensitive to Further Endocrine Therapy[J]. Breast Cancer Research and Treatment . 2003 (2)
  • 2M. Gershanovich,H. A. Chaudri,D. Campos,H. Lurie,A. Bonaventura,M. Jeffrey,F. Buzzi,I. Bodrogi,H. Ludwig,P. Reichardt,N. O’Higgins,G. Romieu,P. Friederich,M. Lassus.Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer[J]. Annals of Oncology . 1998 (6)
  • 3C. Kent Osborne,Michael Jarman,Ray McCague,Ester B. Coronado,Susan G. Hilsenbeck,Alan E. Wakeling.The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth[J]. Cancer Chemotherapy and Pharmacology . 1994 (2)
  • 4XU B,JIANG Z,SHAO Z,et al.Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer:results of a multicentre,double-blind,randomised phase III trial. Cancer Chemother . 2011
  • 5MELLO C A,CHINEN L T,DA SILVA S C,et al.Prolonged time to progression with Fulvestrant for metastatic breast cancer. Medical Oncology . 2010
  • 6ROBERTSON J F,STEGER G G,NEVEN P,et al.Activity of Fulvestrant in HER2-overexpressing advanced breast cancer. Annals of Oncology . 2010
  • 7RobertsonJ,OsborneCK,HowellA,etal.Fulvestrantversus anastrozoleforthetreatmentofadvancedbreastcarcinomainpost menopausalwomen:Aprospectivecombinedanalysisoftwomul ticentertrial. Cancer . 2003
  • 8Buzdar,AU,Hortobagyi,G.Update on endocrine therapy for breast cancer. Clinical Cancer Research . 1998
  • 9Howell,A,Robertson,JFR,Quaresma,AJ,Aschermannova,A,Mauriac,L,Kleeberg,UR,Vergote,I,Erikstein,B,Webster,A,Morris,C.Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology . 2002
  • 10Dombernowsky P,Smith I,Falkson G,et al.Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology . 1998

共引文献8

同被引文献42

  • 1中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:268
  • 2王佳玉,袁芃,马飞,樊英,张频,李青,徐兵河.氟维司群治疗绝经后转移性乳腺癌患者的疗效及安全性[J].中国癌症杂志,2011,21(6):461-464. 被引量:9
  • 3徐迎春,林玉梅,张凤春.乳腺癌内分泌治疗耐药机制研究进展[J].中华肿瘤防治杂志,2006,13(3):227-231. 被引量:8
  • 4Mckeage K,Curran MP,Plosker GL.Fulvestrant:a review of its use in hormone receptor-positive metastatic breast cancer in p0stmenopausa1 women with disease progression following antiestrogen therapy[J].Drugs,2004(6):633-648.
  • 5Nicolas E,Isabelle GV,Stephane F.Ethanol stimulates the secretion of matrix metalloproteinases 2 and 9 in MCF-7 human breast cancer cells[J].Oncology reports,2006(15):603-608.
  • 6Jemal A,Bray F,Center M,et al.Global cancer statistics[J].CA Cancer J Clin,2011(61):69-90.
  • 7Mckenna NJ,Omalley BW.Combinatorial control of gene expression by nuclear receptors and coregulators[J].Cell,2002(108):465-474.
  • 8Natsuka G,Hiromi H,Ichiaki I,et al.Identification of a novel compound that suppresses breast cancer invasiveness by inhibiting transforming growth factor-β signaling via estrogen receptor α[J].Journal of cancer,2014(5):336-343.
  • 9Perey L,Paridaens R,Hawle H,et al.Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors:final results of phase Ⅱ Swiss Group for Clinical Cancer Research Trial[J].Ann Oncol,2007(18):64-69.
  • 10Goto N,Hiyoshi H,Ito I,et al.Estrogen and antiestrogens alter breast cancer invasiveness by modulating the transforming growth factor-beta signaling pathway[J].Cancer Sci,2011(102):1501-1508.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部